Exhibit 10.2
Redacted Version
THIS IS AN AMENDMENT, effective
, to the Monsanto/Paradigm Genetics Collaboration Agreement dated
as of November 17, 1999, and amended May 10, 2000, August 30, 2001,
September 23, 2002, and January 28, 2003 (the
“Agreement”) by and between Paradigm Genetics, Inc., a
Delaware corporation, having a principal place of business at 108
Alexander Drive, Building 1A, P.O. Box 14528, Research Triangle
Park, North Carolina 27709-4528 (“Icoria”) and Monsanto
Company, a Delaware corporation, having a principal place of
business at 800 N. Lindbergh Blvd., St. Louis, Missouri 63167
(“Monsanto”).
WHEREAS, the parties have agreed to
modify the Agreement as set forth herein (the
“Amendment”);
WHEREAS the parties are entering
into an Asset Purchase Agreement as of the same date as this
Amendment;
WHEREAS the parties agree and
acknowledge that there is a substantial uncertainty related to
whether any future royalty payments will be owed by Monsanto to
Icoria pursuant to the Agreement, and, in addition, even if a
future royalty will be paid, it is also uncertain as to the timing
and amount of the royalty payment, and as a result of such
uncertainties, have agreed to the lump sum Royalty Buyout Payment
pursuant to Section 4.2 below;
NOW, THEREFORE, in consideration of
the mutual covenants and agreements hereinafter set forth, the
parties agree as follows:
ARTICLE I
|
1.1
|
In August,
2004, Paradigm Genetics, Inc., changed its name to Icoria, Inc.,
and shall hereafter be referred to as Icoria in this
Amendment.
|
|
1.2
|
Other than as
amended herein, the Agreement shall remain in full force and
effect.
|
|
1.3
|
In the event of
a conflict of provisions between this Amendment and the Asset
Purchase Agreement, the Asset Purchase Agreement shall
control.
|
ARTICLE II
LICENSES
|
2.1
|
Paragraph 2.3
of the Agreement shall be amended to read as follows:
|
2.3 License to Monsanto: Icoria Gene
Patent Rights
Subject to the terms and conditions
of this Agreement and for the consideration as set forth in the
Asset Purchase Agreement, Icoria hereby grants to Monsanto,
Subsidiaries of Monsanto and wholly-owned Affiliates of Monsanto
under Icoria’s interest in the Icoria Gene Patent Rights and
for the life of such Icoria Gene Patent Rights
Portions of this Exhibit were omitted and have
been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.
Redacted Version
a perpetual exclusive, world-wide
license to make and use Project Technology and Monsanto DNA
Information and a perpetual exclusive, world-wide license to
develop, make, have made, import, use, sell, have sold, and offer
to sell Monsanto Licensed Products. Icoria further grants Monsanto
the right to sublicense any of the above rights.
|
2.2
|
Paragraph 2.4
of the Agreement shall be deleted in its entirety and the
restrictions provided therein shall be considered to be
removed.
|
|
2.3
|
Paragraph 2.8
of the Agreement shall be amended to read as follows:
|
|
|
2.8
|
License to
Icoria: research license - Project Technology
|
Monsanto grants Icoria and those
Subsidiaries of Icoria at the Effective Date of this Agreement
under Monsanto’s interest in Licensed Patent Rights except
for those patent rights directed to DNA other than Arabidopsis DNA
and Project Technology a non-exclusive, world-wide license to use
Project Technology and Monsanto DNA Information directed to
Arabidopsis DNA for research purposes only and only to the extent
required for conducting work contemplated by the Excluded Contracts
(defined in the Asset Purchase Agreement) as of the Closing Date of
the Asset Purchase Agreement, and such license shall remain in
effect until the earlier of (1) the date of termination of the last
to terminate of the Excluded Contracts or (2) December 31, 2006.
This license may not be amended, altered, extended or expanded in
any way by means of any amendment to any such Excluded Contract
after the Closing Date of the Asset Purchase Agreement. Such right
shall not extend to any other Monsanto owned or inlicensed
technology, including Monsanto DNA Information that is not from
Arabidopsis except as set forth in Article 2.9.
|
2.4
|
Paragraph 2.9
of the Agreement shall be amended to read as follows:
|
2.9 License to Icoria: research
license - Monsanto Enabling Technology in research crops
Monsanto grants Icoria and
Subsidiaries of Icoria under Monsanto’s interest in Monsanto
Enabling Technology a, nonexclusive, U.S. and Europe only, license
to use Monsanto Enabling Technology in Arabidopsis and tobacco for
research purposes only and only to the extent required for
conducting work contemplated by the Excluded Contracts (defined in
the Asset Purchase Agreement) as of the Closing Date of the Asset
Purchase Agreement, and such license shall remain in effect until
the earlier of (1) the date of termination of the last to terminate
of the Excluded Contracts or (2) December 31,
Portions of this Exhibit were omitted and have
been filed separately with the Secretary of the Commission pursuant
to the Company’s application requesting confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.
Redacted Version
2006. This license may not be
amended, altered, extended or expanded in any way by means of any
amendment to any such Excluded Contract after the Closing Date of
the Asset Purchase Agreement. Such right shall not extend to any
other Monsanto owned or in-licensed technology, whether or not
licensed to Icoria herein, except and to the extent as set forth in
Article 2.8. Notwithstanding the foregoing, such research license
shall not apply to research in herbicide resistance in any plant
species.
|
2.5
|
Paragraph 2.12
of the Agreement shall be deleted in its entirety and the licenses
granted therein shall be considered terminated.
|
ARTICLE III
FUNDED PROGRAM
|
3.1
|
The Project
Plan shall be completed as provided in the Agreement as amended by
the milestone table in attached Exhibit 1. Exhibit 1 describes
targets for Pending Constructs as of May 2, 2005 and Completed
Constructs for all of Q21 and through May 2, 2005. With regard to a
particular assay, a Pending Construct shall be defined as a
Construct on which work for that particular assay has been
initiated as of May 2, 2005, and has been sustained and maintained
according to the Project Plan of the Agreement so as to allow for
satisfactory and timely completion of that assay, but for which
assay complet
|